Pharmaceutical & Life Sciences News

Allergan, Fresenius Will Argue Pharma Patent Cases This Week

Nov. 5, 2018, 8:07 PM

Cases on Allergan’s patents on its blockbuster dry eye drug Restasis and hedge fund manager Kyle Bass’s challenge to Fresenius Kabi’s patent on the anesthetic Diprivan will be argued at the U.S. Court of Appeals for the Federal Circuit this week.

The appeals court is also set to hear oral argument in a case in which Mylan Pharmaceuticals Inc. and other generic companies are challenging the patent on the UCB Inc. seizure treatment Vimpat (lacosamide).

Oral argument at the Federal Circuit is the last chance litigants have to sway judges to their side before a decision comes down. And after...

To read the full article log in. To learn more about a subscription click here.